Oculir

Oculir, founded in 2003, operated from San Diego, United States, with the objective of developing a non-invasive glucose monitoring device. The company's core project was a meter designed to measure glucose levels from the conjunctiva of the eye, eliminating the need for direct contact. This sensor, comparable in size to a mobile phone, would function by being pointed at the eye to capture a reading.

The company successfully secured $7.3 million in a Series A funding round on December 7, 2005. This investment was led by ONSET Ventures and included participation from four other institutional investors, such as CHL Medical Partners and Canaan. Despite this initial funding, the company is now considered deadpooled.

Oculir aimed to serve the diabetes management market by providing a pain-free alternative to traditional blood glucose monitoring methods. The intended user base was individuals with diabetes who require regular glucose checks. The business model likely revolved around the sale of the proprietary glucose monitoring device to consumers and healthcare providers. The primary benefit of their proposed product was the convenience and non-invasive nature of glucose measurement, a significant departure from the standard finger-prick method.

Keywords: non-invasive glucose monitoring, conjunctiva glucose meter, diabetes management device, Oculir funding, ONSET Ventures, CHL Medical Partners, Canaan Partners, medical device startup, Series A funding, blood glucose monitoring